FRMD3

Summary

FRMD3 (FERM domain containing 3, HGNC:24125) is a protein-coding gene on chromosome 9q21.32, encoding FERM domain-containing protein 3 (A2A2Y4). Putative tumor suppressor gene that may be implicated in the origin and progression of lung cancer.

The protein encoded by this gene is a single pass membrane protein primarily found in ovaries. A similar protein in erythrocytes helps determine the shape of red blood cells, but the function of the encoded protein has not been determined. There is some evidence that this is a tumor suppressor gene, and there is also evidence linking defects in this gene to susceptibility to diabetic nephropathy in type 1 diabetes. Several transcript variants encoding different isoforms have been found for this gene.

Source: NCBI Gene 257019 — RefSeq curated summary.

At a glance

• GWAS associations: 7
• Clinical variants (ClinVar): 92 total
• MANE Select transcript: NM_174938

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:24125
Approved symbol	FRMD3
Name	FERM domain containing 3
Location	9q21.32
Locus type	gene with protein product
Status	Approved
Aliases	EPB41L4O, MGC20553
Ensembl gene	ENSG00000172159
Ensembl biotype	protein_coding
OMIM	607619
Entrez	257019

Gene structure

Transcript identifiers

Ensembl transcripts: 11 — 10 protein_coding, 1 protein_coding_CDS_not_defined

ENST00000304195, ENST00000328788, ENST00000376434, ENST00000376438, ENST00000431299, ENST00000465485, ENST00000621208, ENST00000874517, ENST00000874518, ENST00000874519, ENST00000962006

RefSeq mRNA: 6 — MANE Select: NM_174938 NM_001244959, NM_001244960, NM_001244961, NM_001244962, NM_001375487, NM_174938

CCDS: CCDS43840, CCDS59131, CCDS59132, CCDS59133, CCDS75852

Canonical transcript exons

ENST00000304195 — 14 exons

Exon	Start	End
ENSE00000917620	83335516	83335639
ENSE00000982976	83343190	83343287
ENSE00000982977	83313660	83313747
ENSE00001090436	83298748	83298816
ENSE00001090437	83299112	83299186
ENSE00001090438	83309536	83309624
ENSE00001090439	83290603	83290727
ENSE00001197901	83311887	83311975
ENSE00001214627	83310485	83310548
ENSE00001672459	83372913	83372955
ENSE00001732627	83349679	83349757
ENSE00001751790	83389604	83389708
ENSE00001939314	83244622	83248516
ENSE00002729116	83538085	83538401

Expression profiles

Bgee: expression breadth ubiquitous, 250 present calls, max score 99.91.

FANTOM5 (CAGE): breadth broad, TPM avg 4.2178 / max 256.9421, expressed in 843 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
101135	3.4914	763
101131	0.4532	111
101132	0.2600	119
101130	0.0133	4

Top tissues by expression

258 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
secondary oocyte	CL:0000655	99.91	gold quality
kidney epithelium	UBERON:0004819	96.86	gold quality
left ventricle myocardium	UBERON:0006566	96.69	gold quality
apex of heart	UBERON:0002098	96.01	gold quality
oocyte	CL:0000023	95.41	gold quality
cardiac muscle of right atrium	UBERON:0003379	94.93	gold quality
myocardium	UBERON:0002349	94.69	gold quality
ileal mucosa	UBERON:0000331	94.42	gold quality
cardiac ventricle	UBERON:0002082	94.01	gold quality
heart left ventricle	UBERON:0002084	94.01	gold quality
muscle of leg	UBERON:0001383	93.11	gold quality
gastrocnemius	UBERON:0001388	93.07	gold quality
skeletal muscle organ	UBERON:0014892	92.81	gold quality
cortical plate	UBERON:0005343	92.75	gold quality
heart right ventricle	UBERON:0002080	92.71	gold quality
seminal vesicle	UBERON:0000998	92.56	gold quality
hindlimb stylopod muscle	UBERON:0004252	92.45	gold quality
deltoid	UBERON:0001476	92.19	gold quality
tibialis anterior	UBERON:0001385	91.89	gold quality
biceps brachii	UBERON:0001507	91.89	gold quality
quadriceps femoris	UBERON:0001377	91.85	gold quality
vastus lateralis	UBERON:0001379	91.80	gold quality
trigeminal ganglion	UBERON:0001675	91.71	gold quality
epithelial cell of pancreas	CL:0000083	91.24	silver quality
dorsal root ganglion	UBERON:0000044	91.09	gold quality
skeletal muscle tissue	UBERON:0001134	91.07	gold quality
corpus epididymis	UBERON:0004359	91.00	gold quality
cardiac atrium	UBERON:0002081	90.82	gold quality
heart	UBERON:0000948	90.81	gold quality
caput epididymis	UBERON:0004358	90.68	gold quality

Single-cell (SCXA)

Detected in 5 experiment(s), a significant marker in 5.

Experiment	Marker?	Max mean expression
E-MTAB-11268	yes	2174.48
E-CURD-119	yes	43.27
E-MTAB-7249	yes	39.48
E-MTAB-7316	yes	22.96
E-ANND-3	yes	10.37

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

134 targeting FRMD3, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-7110-3P	100.00	73.18	2486
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-6873-3P	100.00	71.42	2626
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-5692B	100.00	71.32	2622
HSA-MIR-5692C	100.00	71.32	2622
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-4776-3P	100.00	68.73	1340
HSA-MIR-656-3P	100.00	72.15	2788
HSA-MIR-3925-3P	100.00	69.95	1237
HSA-MIR-4789-3P	99.99	70.75	2484
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-LET-7F-2-3P	99.98	70.98	2588
HSA-MIR-1185-1-3P	99.98	71.04	2593
HSA-MIR-1185-2-3P	99.98	71.04	2593
HSA-MIR-4715-3P	99.98	66.03	670
HSA-MIR-3688-3P	99.97	72.02	2834
HSA-MIR-548AN	99.97	70.91	2817
HSA-MIR-302C-5P	99.97	72.56	3642
HSA-MIR-493-5P	99.96	72.47	2382
HSA-MIR-5688	99.96	73.23	4504
HSA-MIR-495-3P	99.96	72.81	4197
HSA-MIR-9983-3P	99.94	71.48	3631
HSA-MIR-1-3P	99.93	72.35	1914
HSA-MIR-206	99.93	72.50	1893
HSA-MIR-145-5P	99.92	71.13	1836
HSA-MIR-5195-3P	99.92	70.92	1877

Literature-anchored findings (GeneRIF, showing 6)

• identify FRMD3 as a novel putative tumour suppressor gene suggesting an important role in the origin and progression of lung cancer. (PMID:17260017)
• These analyses reveal a role for FRMD3 in AA T2DN susceptibility. (PMID:21698141)
• model for FRMD3 in diabetic nephropathy proposes a possible transcriptional link through which the polymorphism in the FRMD3 promoter could influence transcriptional regulation within the bone morphogenetic protein (BMP)-signaling pathway (PMID:23434934)
• The risk (G and C) and non-risk (C and T) allele frequencies of the SNPs at the rs1888747 and rs739401 loci of FRMD3 and CARS, respectively, did not differ significantly between the diabetics with (case) and without (control) nephropathy (P > 0.05). (PMID:26909942)
• Hsa-miR-3651 could serve as a novel predictor for in-breast recurrence via FRMD3. (PMID:34865205)
• FRMD3 inhibits the growth and metastasis of breast cancer through the ubiquitination-mediated degradation of vimentin and subsequent impairment of focal adhesion. (PMID:36631457)

Cross-species orthologs

10 orthologs

Organism	Symbol	Gene ID
danio_rerio	frmd3	ENSDARG00000059885
mus_musculus	Frmd3	ENSMUSG00000049122
rattus_norvegicus	Frmd3	ENSRNOG00000006503
drosophila_melanogaster	yrt	FBGN0004049
drosophila_melanogaster	cora	FBGN0010434
drosophila_melanogaster	Frmd5	FBGN0032225
caenorhabditis_elegans	erm-1	WBGENE00001333
caenorhabditis_elegans	frm-1	WBGENE00001488
caenorhabditis_elegans		WBGENE00001489
caenorhabditis_elegans	frm-4	WBGENE00001491

Paralogs (10): MYLIP (ENSG00000007944), EPB41L2 (ENSG00000079819), EPB41L3 (ENSG00000082397), EPB41L1 (ENSG00000088367), EPB41L4B (ENSG00000095203), EPB41L5 (ENSG00000115109), EPB41L4A (ENSG00000129595), FRMD6 (ENSG00000139926), EPB41 (ENSG00000159023), FRMD5 (ENSG00000171877)

Protein

Protein identifiers

FERM domain-containing protein 3 — A2A2Y4 (reviewed: A2A2Y4)

Alternative names: Band 4.1-like protein 4O, Ovary type protein 4.1

All UniProt accessions (2): A2A2Y4, Q5JV61

UniProt curated annotations — full annotation on UniProt →

Function. Putative tumor suppressor gene that may be implicated in the origin and progression of lung cancer.

Subcellular location. Membrane.

Tissue specificity. Ovary-specific.

Isoforms (5)

UniProt ID	Names	Canonical?
A2A2Y4-1	1	yes
A2A2Y4-2	2
A2A2Y4-3	3
A2A2Y4-4	4
A2A2Y4-5	5

RefSeq proteins (6): NP_001231888, NP_001231889, NP_001231890, NP_001231891, NP_001362416, NP_777598* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000299	FERM_domain	Domain
IPR000798	Ez/rad/moesin-like	Family
IPR011993	PH-like_dom_sf	Homologous_superfamily
IPR014352	FERM/acyl-CoA-bd_prot_sf	Homologous_superfamily
IPR014847	FA	Domain
IPR018979	FERM_N	Domain
IPR018980	FERM_PH-like_C	Domain
IPR019747	FERM_CS	Conserved_site
IPR019748	FERM_central	Domain
IPR019749	Band_41_domain	Domain
IPR029071	Ubiquitin-like_domsf	Homologous_superfamily
IPR035963	FERM_2	Homologous_superfamily

Pfam: PF00373, PF08736, PF09379, PF09380

UniProt features (13 total): splice variant 6, sequence conflict 2, chain 1, transmembrane region 1, sequence variant 1, domain 1, region of interest 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-A2A2Y4-F1	75.03	0.45

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 139 (showing top): BENPORATH_ES_WITH_H3K27ME3, RODWELL_AGING_KIDNEY_NO_BLOOD_DN, TGIF_01, GOBP_ACTOMYOSIN_STRUCTURE_ORGANIZATION, CHIANG_LIVER_CANCER_SUBCLASS_CTNNB1_UP, chr9q21, GOMF_CYTOSKELETAL_PROTEIN_BINDING, HORIUCHI_WTAP_TARGETS_UP, GSE14415_INDUCED_TREG_VS_FOXP3_KO_INDUCED_TREG_IL2_CULTURE_DN, HMGA1_TARGET_GENES, HOXC6_TARGET_GENES, LHX9_TARGET_GENES, TFEB_TARGET_GENES, ZIM3_TARGET_GENES, ZNF22_TARGET_GENES

GO Biological Process (1): actomyosin structure organization (GO:0031032)

GO Molecular Function (2): cytoskeletal protein binding (GO:0008092), protein binding (GO:0005515)

GO Cellular Component (2): cytoskeleton (GO:0005856), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
actin cytoskeleton organization	1
protein binding	1
binding	1
intracellular membraneless organelle	1
cellular anatomical structure	1

Protein interactions and networks

STRING

482 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
FRMD3	CPVL	Q9H3G5	668
FRMD3	A0A2R8YEI5	A0A2R8YEI5	663
FRMD3	LRRIQ3	A6PVS8	645
FRMD3	MYH9	P35579	628
FRMD3	RASEF	Q8IZ41	622
FRMD3	CHN2	P52757	621
FRMD3	SAMD5	Q5TGI4	616
FRMD3	TMC7	Q7Z402	612
FRMD3	NIBAN3	Q86XR2	596
FRMD3	ELMO1	Q92556	571
FRMD3	CNDP1	Q96KN2	542
FRMD3	C1orf94	Q6P1W5	518
FRMD3	CARS1	P49589	507
FRMD3	CARS2	Q9HA77	501
FRMD3	MS4A1	P08984	488

IntAct

42 interactions, top by confidence:

A	B	Type	Score
FRMD3	ZFPL1	psi-mi:“MI:0915”(physical association)	0.560
FRMD3	PLPP4	psi-mi:“MI:0915”(physical association)	0.560
FRMD3	CMTM7	psi-mi:“MI:0915”(physical association)	0.560
FRMD3	TMEM97	psi-mi:“MI:0915”(physical association)	0.560
FRMD3	JAGN1	psi-mi:“MI:0915”(physical association)	0.560
FRMD3	TMEM201	psi-mi:“MI:0915”(physical association)	0.560
FRMD3	SERP2	psi-mi:“MI:0915”(physical association)	0.560
FRMD3	TMEM218	psi-mi:“MI:0915”(physical association)	0.560
FRMD3	SERP1	psi-mi:“MI:0915”(physical association)	0.560
FRMD3	NRM	psi-mi:“MI:0915”(physical association)	0.560
FRMD3	SLC35A4	psi-mi:“MI:0915”(physical association)	0.560
FRMD3	CYB5B	psi-mi:“MI:0915”(physical association)	0.560
nleA/espI	FRMD3	psi-mi:“MI:0915”(physical association)	0.370
FRMD3	nleA/espI	psi-mi:“MI:0915”(physical association)	0.370
FRMD3	FAM234B	psi-mi:“MI:0914”(association)	0.350
	NFIB	psi-mi:“MI:0914”(association)	0.350
FRMD3	ATP5F1D	psi-mi:“MI:0914”(association)	0.350
ZFPL1	FRMD3	psi-mi:“MI:0915”(physical association)	0.000
TMEM218	FRMD3	psi-mi:“MI:0915”(physical association)	0.000
SERP1	FRMD3	psi-mi:“MI:0915”(physical association)	0.000
NRM	FRMD3	psi-mi:“MI:0915”(physical association)	0.000
SLC35A4	FRMD3	psi-mi:“MI:0915”(physical association)	0.000
CYB5B	FRMD3	psi-mi:“MI:0915”(physical association)	0.000
PLPP4	FRMD3	psi-mi:“MI:0915”(physical association)	0.000
CMTM7	FRMD3	psi-mi:“MI:0915”(physical association)	0.000
TMEM97	FRMD3	psi-mi:“MI:0915”(physical association)	0.000
JAGN1	FRMD3	psi-mi:“MI:0915”(physical association)	0.000
TMEM201	FRMD3	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (33): ATP5D (Affinity Capture-MS), ATP5O (Affinity Capture-MS), OXA1L (Affinity Capture-MS), COLEC12 (Affinity Capture-MS), LCLAT1 (Affinity Capture-MS), KLHL15 (Affinity Capture-MS), REEP4 (Affinity Capture-MS), KIAA1467 (Affinity Capture-MS), GYLTL1B (Affinity Capture-MS), CKAP4 (Affinity Capture-MS), LMBR1 (Affinity Capture-MS), FRMD3 (Affinity Capture-RNA), FRMD3 (Two-hybrid), FRMD3 (Two-hybrid), FRMD3 (Two-hybrid)

ESM2 similar proteins: A0JM95, A1A4S6, A2A2Y4, A4II46, A4IJ06, A6NI28, B2RQE8, B5DFQ4, F1LVW7, O60879, O60890, O70566, O95267, P0C7A6, P0CAX5, Q02384, Q07889, Q07890, Q08DP6, Q0P4Q4, Q28EC1, Q4V7P7, Q566W7, Q5R6F6, Q5R803, Q5U4T3, Q62245, Q69ZK0, Q6DBW1, Q6DHR3, Q6NTL4, Q6PCS4, Q6Y5D8, Q6ZM89, Q7YQL5, Q7YQL6, Q8AVG0, Q8BHD4, Q8IV61, Q8N9B8

Diamond homologs: A2A2Y4, A2AD83, A2ALK8, B2RYE5, F1LYQ8, F1P065, F8VPU2, O43491, O57457, O70318, O94887, P11171, P11434, P26045, P28191, P29074, P48193, P52963, Q0P4Q4, Q54K81, Q58CU2, Q5FVG2, Q5R803, Q5RAB8, Q6P5H6, Q6Q7P4, Q6ZUT3, Q7Z6J6, Q8BGS1, Q8BHD4, Q91VS8, Q9H329, Q9H4G0, Q9HCM4, Q9HCS5, Q9JMC8, Q9MYU8, Q9N179, Q9V8R9, Q9WTP0

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

92 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	67
Likely benign	1
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

3986 predictions. Top by Δscore:

Variant	Effect	Δscore
9:83248134:CTTG:C	donor_gain	1.0000
9:83248136:TG:T	donor_gain	1.0000
9:83248402:T:TA	donor_gain	1.0000
9:83248417:T:TA	donor_gain	1.0000
9:83290597:ACTT:A	donor_loss	1.0000
9:83290598:CTT:C	donor_loss	1.0000
9:83290599:TTA:T	donor_loss	1.0000
9:83290600:TA:T	donor_loss	1.0000
9:83290601:A:AC	donor_gain	1.0000
9:83290601:AC:A	donor_gain	1.0000
9:83290601:ACCC:A	donor_loss	1.0000
9:83290602:C:CC	donor_gain	1.0000
9:83290602:CC:C	donor_gain	1.0000
9:83290602:CCCT:C	donor_gain	1.0000
9:83290726:CT:C	acceptor_gain	1.0000
9:83290727:TCTG:T	acceptor_loss	1.0000
9:83290728:C:CC	acceptor_gain	1.0000
9:83290728:CTGA:C	acceptor_loss	1.0000
9:83290729:T:G	acceptor_loss	1.0000
9:83298743:CTCA:C	donor_loss	1.0000
9:83298745:CA:C	donor_loss	1.0000
9:83298746:A:AT	donor_loss	1.0000
9:83298747:C:G	donor_loss	1.0000
9:83298812:TCCCA:T	acceptor_gain	1.0000
9:83298813:CCCA:C	acceptor_gain	1.0000
9:83298813:CCCAC:C	acceptor_gain	1.0000
9:83298814:CCA:C	acceptor_gain	1.0000
9:83298814:CCAC:C	acceptor_gain	1.0000
9:83298815:CA:C	acceptor_gain	1.0000
9:83298815:CAC:C	acceptor_gain	1.0000

AlphaMissense

3966 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
9:83309570:A:G	W298R	1.000
9:83309570:A:T	W298R	1.000
9:83309572:A:G	L297P	1.000
9:83309580:G:C	C294W	1.000
9:83309581:C:T	C294Y	1.000
9:83311888:A:G	W258R	1.000
9:83311888:A:T	W258R	1.000
9:83311947:C:T	G238E	1.000
9:83313663:G:C	C227W	1.000
9:83313671:G:C	H225D	1.000
9:83343240:A:G	L141P	1.000
9:83343243:C:G	R140P	1.000
9:83343258:T:A	D135V	1.000
9:83343258:T:G	D135A	1.000
9:83343259:C:G	D135H	1.000
9:83349720:G:C	F111L	1.000
9:83349720:G:T	F111L	1.000
9:83349722:A:G	F111L	1.000
9:83372948:A:G	L87P	1.000
9:83372948:A:T	L87H	1.000
9:83372950:C:A	W86C	1.000
9:83372950:C:G	W86C	1.000
9:83372952:A:G	W86R	1.000
9:83372952:A:T	W86R	1.000
9:83389696:C:A	G54W	1.000
9:83309541:A:C	F307L	0.999
9:83309541:A:T	F307L	0.999
9:83309542:A:G	F307S	0.999
9:83309543:A:G	F307L	0.999
9:83309560:C:T	G301E	0.999

dbSNP variants (sampled 300 via entrez): RS1000014571 (9:83498251 T>C), RS1000028099 (9:83344954 T>C), RS1000037327 (9:83307830 A>G,T), RS1000049751 (9:83286588 T>C), RS1000050735 (9:83475857 C>T), RS1000050976 (9:83562468 C>T), RS1000066898 (9:83485971 T>C), RS1000084306 (9:83436440 CA>C), RS1000086053 (9:83568172 CT>C), RS1000103296 (9:83388306 G>C), RS1000113120 (9:83451817 C>T), RS1000116725 (9:83258879 A>C,T), RS1000128851 (9:83319865 G>A,T), RS1000134759 (9:83442547 A>G), RS1000135898 (9:83265301 G>A)

Disease associations

OMIM: gene MIM:607619 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

7 associations (top):

Study	Trait	p-value
GCST002591_22	Lewy body disease	9.000000e-06
GCST002591_40	Lewy body disease	2.000000e-06
GCST003773_8	Loneliness (multivariate analysis)	4.000000e-07
GCST004384_4	Hypertension	1.000000e-08
GCST004388_1	Blood pressure traits (multi-trait analysis)	7.000000e-09
GCST005221_1	Insulin sensitivity index	2.000000e-07
GCST009391_2131	Metabolite levels	6.000000e-06

EFO canonical traits (7, from GWAS)

EFO ID	Trait name
EFO:0006799	Lewy body dementia measurement
EFO:0007865	loneliness measurement
EFO:0005763	pulse pressure measurement
EFO:0006335	systolic blood pressure
EFO:0006336	diastolic blood pressure
EFO:0004471	insulin sensitivity measurement
EFO:0010383	phosphatidylcholine 36:5 measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

52 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, increases expression, affects expression	5
mercuric bromide	decreases expression, affects cotreatment	2
Air Pollutants	increases expression, decreases expression	2
Benzo(a)pyrene	decreases expression	2
Estradiol	affects cotreatment, decreases expression, increases expression	2
Phenylmercuric Acetate	affects cotreatment, decreases expression	2
Cyclosporine	decreases expression	2
p-Chloromercuribenzoic Acid	affects cotreatment, decreases expression	2
aristolochic acid I	decreases expression	1
FR900359	decreases phosphorylation	1
methylmercuric chloride	decreases expression	1
triphenyl phosphate	affects expression	1
pirinixic acid	affects binding, increases activity, increases expression	1
bisphenol A	decreases expression	1
2,5,2’,5’-tetrachlorobiphenyl	increases expression	1
trichostatin A	increases expression	1
arsenite	increases methylation	1
mono-(2-ethylhexyl)phthalate	increases expression	1
sodium arsenite	affects splicing, decreases expression	1
ochratoxin A	increases expression	1
aflatoxin B2	increases methylation	1
nickel sulfate	increases expression	1
CGP 52608	affects binding, increases reaction	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression, increases expression	1
abrine	decreases expression	1
dorsomorphin	affects cotreatment, decreases expression, increases expression	1
MRK 003	decreases expression	1
bisphenol S	affects cotreatment, decreases methylation	1
jinfukang	affects cotreatment, increases expression	1
gardiquimod	increases expression, decreases reaction	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.